DiGenesis Platform

The DiGenesis Platform, developed by Unlearn.AI, is a solution aimed at accelerating clinical innovation and drug development. According to the vendor, this platform leverages generative machine learning methods to predict individual health outcomes, making it a potentially valuable tool for pharmaceutical and biotech companies of various sizes. Professionals in the pharmaceutical and biotech industries, such as researchers, clinical trial professionals, healthcare professionals, and data scientists, may find the advanced capabilities of the DiGenesis Platform beneficial.

Key Features

AI-powered digital twins: The DiGenesis Platform utilizes AI-powered digital twins to simulate individual health outcomes over time. These digital twins are generated using generative machine learning models trained on historical, individual-level data. According to the vendor, they provide longitudinal predictions of potential health outcomes for each patient.

Compare potential health outcomes: The DiGenesis Platform allows for the simulation of 'what if?' scenarios to compare potential health outcomes. It estimates relative treatment effects by comparing different scenarios and their impact on health outcomes. This feature enables researchers to evaluate the effectiveness of different treatments and interventions, helping in estimating the relative benefits and risks associated with different treatment options, according to the vendor.

AI-powered RCTs: The DiGenesis Platform is designed for use in AI-powered clinical trials, specifically TwinRCTs. According to the vendor, these trials leverage patients' digital twins to enable highly powered studies with smaller control groups. They claim that these trials can reach full enrollment faster compared to traditional trial designs, providing more power with smaller control groups.

Collaborations with pharma and biotech: The DiGenesis Platform collaborates with innovators in the pharmaceutical and biotech industries to accelerate clinical drug development. According to the vendor, it provides advanced AI capabilities to enhance the efficiency and effectiveness of clinical trials, aiming to eliminate trial and error in medicine and improve patient outcomes.

Regulatory qualified framework: The DiGenesis Platform incorporates a regulatory-qualified framework called PROCOVA™, used to estimate the treatment effect in TwinRCTs. According to the vendor, this framework ensures that the results obtained from TwinRCTs are precise, unbiased, and meet regulatory standards. They state that the PROCOVA™ framework has received a qualification opinion from the European Medicines Agency (EMA).

Digital twin generators: The DiGenesis Platform offers disease-specific models called digital twin generators (DTGs). These DTGs are trained on curated, indication-specific clinical data and generate patient-specific digital twins that predict how an individual patient's health will change over time. The vendor claims that the DTGs are available for various indications, including Alzheimer's Disease, Parkinson's Disease, and Crohn's Disease.